BACE1 and Alzheimer disease: In this review, the β-secretase activity of only BACE1 is discussed, based on its suitability as a target for AD therapeutics, evidenced by the attainment of central Aβ reduction of greater than 90% in numerous trials (reviewed in Section 3.4 below).